GMP-Webinar: Revised Annex 17 – What´s new?

05 December 2017, 14.00 – 15.30 h CET

Course No 16386

Our Service

Costs

This training/webinar cannot be booked. To find alternative dates for this training/webinar or similar events please see the events list by topic.

For many training courses and webinars, there are also recordings you can order and watch any time. You can find these recordings in a list sorted by topic.

Or simply send us your inquiry by using the following contact form.

Send request

* also payable by credit card

If you have any questions, please contact us:
Tel.: +49 (0)6221 / 84 44 0 E-Mail: info@gmp-compliance.org

Speakers

Dr Rainer Gnibl, GMP Inspector, District Government of Upper Bavaria, Germany

Dr Rainer Gnibl is pharmacist and GMP Inspector for the District Government and the EMA and performs GMP inspections worldwide. Before that, he was working for the Bavarian Ministry of Environment and Health. Rainer Gnibl also holds a lectureship at the University Erlangen-Nürnberg.

Background

The revised Annex 17 of Eudralex volume 4 is intended to outline the requirements for application of a Real Time Release Testing (RTRT) approach in manufacturing, where the control of critical process parameters and relevant critical quality attributes may be used as an alternative to routine finished product testing of medicinal products. The previous Annex 17 only focused on the application of Parametric Release for the routine release of terminally sterilized products waiving the performance of a test for sterility on the basis of successful demonstration that predetermined and validated sterilizing conditions have been achieved. Recent advances in the application of process analytical technology (PAT), quality by design (QbD) and quality risk management (QRM) principles to pharmaceutical development and manufacturing have shown that the appropriate combination of process controls together with timely monitoring and verification of pre-established critical quality attributes provides greater assurance of product quality than finished product testing alone. The revised Annex 17 is brought into line with ICH Q8- Q12 documents and will detail regulatory expectations for a batch release system based on the information collected during the manufacturing process, through product knowledge and process understanding and control.

Target Group

The webinar targets executives and staff from development, production and quality units, as well as quality assurance, who are in charge of being compliant with specifications regarding critical quality parameters of pharmaceutical products which have been determined during development phase. But also Qualified Persons responsible for the review and release of products are within the target group of this webinar.

Technical Requirements

For our webinars, we use Cisco WebEx, one of the leading suppliers of online meetings. At http://www.webex.com/test-meeting.htm you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

Programme

The control of critical process parameters (CPPs) and relevant critical quality attributes (CQAs) may be used as an alternative to routine finished product testing of medicinal products. Therefore, the following topics are discussed during the webinar:

Which are the requirements for application of a Real Time
Release Testing (RTRT) approach in manufacturing?
How are CPPs and relevant CQAs controlled?
Can the Qualified Person (QP) certify batches based on the compliance of the process data to the approved release criteria together with appropriate GMP compliance?
Are active substances and intermediates included in this new approach?
What are the expected benefits and hurdles?

Go back